Antigenic Peptides Or Proteins Patents (Class 530/806)
  • Patent number: 8992936
    Abstract: Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: March 31, 2015
    Assignees: Research Foundation of the State University of New York, Brookhaven Sciences Associates, LLC, University of Rochester
    Inventors: Benjamin J. Luft, John J. Dunn, Shohei Koide, Catherine L. Lawson
  • Patent number: 8986703
    Abstract: Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 24, 2015
    Assignee: PepTcell, Ltd.
    Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderley
  • Patent number: 8808712
    Abstract: The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X1-A-B-X2-Y-X3-(Y)n-X4-(Y)n-X5??(1) (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: August 19, 2014
    Assignee: Osaka University
    Inventors: Toshihiro Horii, Ken Ishii, Takahiro Tougan
  • Patent number: 8809494
    Abstract: Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided. In addition methods for identifying agents which inhibit the function of these proteins as chemotherapeutic and/or immunologic agents for treatment and prevention of malaria infections are provided. Compositions for treatment and prevention of malaria infections and methods for preventing and treating malaria infections are also provided.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: August 19, 2014
    Assignee: Drexel University
    Inventors: Lawrence W. Bergman, Akhil B. Vaidya
  • Patent number: 8759114
    Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 24, 2014
    Assignee: Stichting Voor de Technische Wetenschappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 8722053
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: May 13, 2014
    Assignee: Pfizer Vaccines LLC
    Inventors: Brian Robert Champion, David Robert Stead, Paul Andrew Wright
  • Patent number: 8685662
    Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 1, 2014
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
  • Patent number: 8642048
    Abstract: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: February 4, 2014
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Edwin W. Ades, Scott E. Johnson, Danny L. Jue, Jacquelyn S. Sampson, George M. Carlone
  • Patent number: 8623383
    Abstract: The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group Rickettsia. The invention also relates to a method for the use of the recombinant proteins, either singly or in combination, in detection and diagnostic assays of spotted fever. The proteins can also be used to induce immune response against spotted fever group Rickettsia.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: January 7, 2014
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Wei-Mei Ching
  • Patent number: 8563007
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 22, 2013
    Assignee: Wyeth Holdings Corporation
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Patent number: 8545853
    Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: October 1, 2013
    Assignees: Universite de Liege, Centre d'Economie Rurale, Universite Libre de Bruxelles
    Inventors: Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet
  • Patent number: 8529902
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: September 10, 2013
    Assignee: Genmab A/S
    Inventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
  • Patent number: 8501427
    Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: August 6, 2013
    Assignee: University College Cardiff Consultants Limited
    Inventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
  • Patent number: 8486412
    Abstract: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR? immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: July 16, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Lynn C. Hartmann, Kimberly R. Kalli, Christopher J. Krco
  • Patent number: 8481332
    Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 9, 2013
    Assignee: Stichting Voor de Technische Wetenshappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 8475801
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: July 2, 2013
    Assignee: Pfizer Vaccines, LCC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
  • Patent number: 8470340
    Abstract: Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: June 25, 2013
    Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, Universita degli Studi del Molise
    Inventors: Peter Beernink, Franco Felici, Dan M. Granoff
  • Patent number: 8389678
    Abstract: Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum. Such recombinant protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as kits for ELISA is also disclosed.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: March 5, 2013
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: John G. Hoey, Denise P. Dimitrov, Lisa B. Huang, Martin E. Adelson, Eli Mordechai
  • Patent number: 8389227
    Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: March 5, 2013
    Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron
    Inventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
  • Patent number: 8318909
    Abstract: Based on the discovery of the nucleotide and amino acid differences which distinguish the Gova and Govb allelic forms of the membrane glycoprotein CD109, and which comprise the biallelic Gov platelet alloantigen system, compositions and methods are provided for determining the Gov genotype and phenotype of individuals. Also provided, on the basis of this discovery, are compositions and methods for treating disorders associated with Gov alloantigen incompatibility, such as the bleeding disorders post-transfusion purpura, post-transfusion platelet refractoriness, and neonatal alloimmune thrombocytopenia. The two allelic forms of CD109 differ by a single amino acid. The Gova allelic form has Tyr at amino acid position 703 in the CD109 sequence. The Govb allelic form has Ser at the same position. This amino acid difference is due to a single change, from A for the Gova allele to C for the Govb allele, in the CD109 gene.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: November 27, 2012
    Inventors: Andre Schuh, Willem Ouwehand
  • Patent number: 8278119
    Abstract: By detecting an antibody which immunologically reacts with amylase ?2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. For instance, detection of this antibody is carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 511 of human amylase ?2-A (SEQ ID NO: 1).
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: October 2, 2012
    Assignees: University of Yamanashi, Cosmic Corporation
    Inventors: Tetsuro Kobayashi, Toyoshi Endo, Atsushi Sakuraoka
  • Patent number: 8187600
    Abstract: The invention relates to the use of a polypeptide that comprises i) a first portion comprising the part of human Fc that binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody that may be used to stimulate a cytotoxic T cell response against pathogens and tumor cells in patients in need of such treatment.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: May 29, 2012
    Assignees: Scancell Limited, Cancer Research Technology Limited
    Inventors: Linda Gillian Durrant, Tina Parsons, Adrian Robins
  • Patent number: 8133873
    Abstract: A recombinant gene sequence that comprises human SLC gene, antigen gene, and IgG1-Fc fragment gene, wherein the SLC gene is linked upstream to the antigen gene, and the IgG1-Fc fragment is linked downstream to the antigen gene. This invention also relates to the application of the recombinant gene sequence in the preparation of gene vaccine.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: March 13, 2012
    Assignee: Cancer Institute, Chinese Academy of Medical Sciences
    Inventors: Shuren Zhang, Chen Lin, Wenxin Sun, Hanjun Qin, Chunxia Zhou, Xiao Liang, Dongmei Wang, Wenbo Ma, Xueyan Zhang, Ming Fu
  • Patent number: 8114606
    Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: February 14, 2012
    Assignee: The Board of Trustees of Southern Illinois University
    Inventor: Deliang Cao
  • Patent number: 8025891
    Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydophila.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: September 27, 2011
    Assignee: The Regents of the University of California
    Inventors: Richard S. Stephens, Diane Kawa
  • Patent number: 8012932
    Abstract: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: September 6, 2011
    Assignee: U.S. Environmental Protection Agency
    Inventor: Gary R. Klinefelter
  • Patent number: 7988979
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: August 2, 2011
    Assignees: J. Craig Venter Institute, Inc., Novartis AG
    Inventors: Claire M. Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Maria Rosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulo Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, Craig Venter
  • Patent number: 7981865
    Abstract: Antigenic fragments of human Factor VIII polypeptide, pharmaceutical compositions which contain these fragments, and complexes containing these peptides and a carrier protein or peptide.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: July 19, 2011
    Assignee: Department Central De Fractionment De La Croix-Rouge Scrl
    Inventors: Ruth Laub, Mario Di Giambattista
  • Patent number: 7951910
    Abstract: The invention relates to peptides with the Marburg I polymorphism of FSAP and to their preparation and uses, in particular in therapy and diagnosis. The peptides are suitable for use as immunizing antigens for preparing FSAP MR I specific antibodies.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: May 31, 2011
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Herbert Schwarz, Harald Althaus, Bodo Fischer, Thomas Wissel
  • Patent number: 7951909
    Abstract: The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid ? (A?) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicits a site-directed immune response against the main functional/regulatory site of the A? peptide and generate antibodies, which are highly cross-reactive to the soluble A?1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble A?1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the “soluble A?-derived toxins”; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: May 31, 2011
    Assignee: United Biomedical, Inc.
    Inventor: Chang Yi Wang
  • Patent number: 7910110
    Abstract: The present invention relates to vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to receptors on the surface of specific cell types.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: March 22, 2011
    Assignee: BigDNA Limited
    Inventors: John Bernard March, Jason Clark
  • Patent number: 7892557
    Abstract: The present invention relates to the identification of antigenic and immunogenic peptide-based mimicry of mannose-containing cell-wall compounds characterizing mycobacterial infectious agents, such as Mycobacterium tuberculosis. Amino acid molecules which are mimotopes of mannosylated lipoglycans, such as lipoarabinomannan (ManLAM), including at least one of the following characteristics: (a) being capable of binding to ManLAM binding antibodies; (b) being capable of eliciting production of ManLAM binding antibodies, are provided. Also diagnostic methods for diagnosing mycobacterial infections and methods of vaccinating subjects against such infections. The diagnostic and vaccination methods employ the provided amino acid molecules. Accordingly, a diagnostic kit and a vaccine for executing the aforementioned methods are provided.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: February 22, 2011
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem
    Inventors: Herve Bercovier, Ayelet Barenholz, Jonathan Gershoni
  • Patent number: 7888133
    Abstract: The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrulline or an analogue thereof, and nonG is an amino acid other than glycine.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: February 15, 2011
    Assignee: Stichting Voor De Technische Wetenschappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 7871628
    Abstract: The present invention relates to peptide mimics of a conserved gonococcal epitope of Neisseria gonorrhoeae, which epitope is not found on human blood group antigens. This invention also relates to methods and compositions using such peptide mimics for the prophylaxis of gonorrheal infections.
    Type: Grant
    Filed: February 26, 2007
    Date of Patent: January 18, 2011
    Assignee: University of Massachusetts
    Inventors: Peter A. Rice, Jutamas Ngampasutadol, Sunita Gulati
  • Patent number: 7867498
    Abstract: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: January 11, 2011
    Assignee: Novartis AG
    Inventors: Rino Rappuoli, Guido Grandi
  • Patent number: 7794734
    Abstract: Vaccine preparations for the prevention and treatment of bovine respiratory disease (BRD) and, in particular, its most severe form, termed “shipping fever”, are provided. The preparations comprise chimeric proteins comprising immunodominant epitopes of recombinant Mannheimia haemolytica outer membrane protein PlpE, and immunodominant epitopes of recombinant M. haemolytica leukotoxin.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: September 14, 2010
    Assignee: The Board of Regents for Oklahoma State University
    Inventors: Sahlu Ayalew, Anthony W. Confer
  • Patent number: 7794731
    Abstract: The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of making a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against Yersinia pestis.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: September 14, 2010
    Assignee: Wake Forest University Health Sciences
    Inventors: Steven B. Mizel, Anna Nichole Honko
  • Patent number: 7767419
    Abstract: The invention provides a method to efficiently express high levels of a recombinant untagged NT-proBNP for use as a calibrator in NT-proBNP immunoassays.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: August 3, 2010
    Assignee: Nexus DX, Inc.
    Inventors: Azhar Alvi, William Yajima, Roshana Sikora, George Jackowski, Mee-Ra Hong
  • Patent number: 7678379
    Abstract: The invention provides novel Class I HLA-A2 and Class II HLA-DR4-restricted epitopes and methods for their use in detecting T-cells in peripheral blood specific for infection or latency of mycobacterial infection, including M. tuberculosis and M. leprae as others. For example, methods for diagnosing the presence of infection or exposure by M. tuberculosis utilize multimers of HLA monomers or modified monomers having a bound HLA-binding peptide to perform high throughput screening of patient PBLs. The methods can be used for monitoring the success of anti mycobacterial treatment in patients and to screen vaccines and drugs for effectiveness in treating or preventing exposure, infection and latency of mycobacteria in humans.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: March 16, 2010
    Assignee: Beckman Coulter, Inc.
    Inventor: Markus Joseph Maeurer
  • Patent number: 7655249
    Abstract: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: February 2, 2010
    Assignee: Corixa Corporation
    Inventors: Alexander Gaiger, Patricia D. McNeill
  • Patent number: 7576176
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: August 18, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • Patent number: 7553494
    Abstract: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: June 30, 2009
    Assignee: Corixa Corporation
    Inventors: Alexander Gaiger, Patricia D McNeill, Nomalie Jaya
  • Patent number: 7538189
    Abstract: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: May 26, 2009
    Assignee: Isotechnika Inc.
    Inventors: Selvaraj Naicker, Randall W. Yatscoff, Robert T. Foster
  • Patent number: 7521421
    Abstract: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: April 21, 2009
    Assignee: Isotechnika Inc.
    Inventors: Selvaraj Naicker, Randall W. Yatscoff, Robert T. Foster
  • Patent number: 7517533
    Abstract: Proteins derived from Pseudomonas aeruginosa are antigenic and are of use in the treatment, prophylaxis and diagnosis of P. aeruginosa infection.
    Type: Grant
    Filed: December 4, 2000
    Date of Patent: April 14, 2009
    Assignee: The University of Canberra
    Inventors: Allan W. Cripps, Jennelle M. Kyd, Linda D. Thomas
  • Patent number: 7485708
    Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: February 3, 2009
    Assignee: University of Arkansas
    Inventors: A. Wesley Burks, Jr., Gary A. Bannon, Hugh A. Sampson, Ricki M. Helm, J. Steven Stanley, Patrick A. Rabjohn
  • Patent number: 7485305
    Abstract: The present invention relates to a novel allergen from house-dust mites, to polypeptides derived from said allergen and polynucleotides encoding the same. Furthermore, the invention provides antibodies directed against the allergen and to the use of the polypeptides, polynucleotides and/or antibodies in therapy and diagnosis of allergic disorders.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: February 3, 2009
    Assignee: Biomay AG
    Inventors: Rudolf Valenta, Peter Valent, Margit Weghofer, Susanne Vrtala, Maria-Theresia Krauth
  • Patent number: 7482010
    Abstract: The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: January 27, 2009
    Assignee: Phadia AB
    Inventors: Rudolf Valenta, Susanne Vrtala, Sabine Stummfoll, Hans Grönlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
  • Patent number: RE40948
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: October 27, 2009
    Assignees: The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of Utah
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White
  • Patent number: RE43472
    Abstract: A novel isoform of tropomyosin is disclosed. The isoform is closely related to epithelial human tropomyosin (hTM) and more particularly to hTM5 except the last coding exon. The novel isoform, is called TC22. Northern blot analysis with TC22-specific probe revealed that normal culture cell lines and normal epithelial tissues expressed very little, if at all, TC22 message, whereas their transformed counterparts and tumor tissues including dysfunction of the alimentary canal, significantly increased the expression of TC22. Assays directed at determining the level of TC22 are useful in diagnostics and therapeutics of dysfunction of the alimentary canal. Specific antibodies and mimics for TC22 are also disclosed for use in diagnostics and therapeutics of dysfunction of the alimentary canal.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: June 12, 2012
    Assignees: University of Medicine and Dentistry of New Jersey, University of Iowa Research Foundation
    Inventors: Kiron M. Das, Jim Jung-Ching Lin